Use of Radium-223 in Clinical Practice: a Radiation Oncologist's Experience - Daniel Spratt

November 8, 2016

Dr. Daniel Spratt begins his video lecture with an overview of Radium-223 and highlights from the ALSYMPCA trial and improvement of overall survival.  Dr. Spratt discusses the current use of Radium-223 and how applicable ALSYMPCA’s results are for today’s patient. The lecture concludes with a look at how to optimize the use of the use of Radium-223. Importantly, by giving Radium-223 as 3rd or 4th line CRPC treatment, it is unlikely the patient will complete all 6 cycles.  Increasing total burden of disease and failure to complete all 6 cycles of Radium-223 are associated with worse outcomes.


Dan Spratt, M.D., is an Assistant Professor in the Department of Radiation Oncology at the University of Michigan Health System. In addition to his medical training at Vanderbilt University where he obtained his medical degree, he completed his radiation oncology residency at Memorial Sloan Kettering Cancer Center.  While at Sloan Kettering he completed a research fellowship focused on androgen receptor signaling and non-invasive imaging in prostate cancer.  Dr. Spratt is the co-chair for the radiobiology and radiotherapy working group for the Prostate Cancer Foundation. He also serves as the lead on the American College of Radiology Unsealed Source national guidelines.  Additionally, Dr. Spratt co-led the International Spine Consensus Guidelines for high dose spine radiosurgery, and currently is the co-director of the University of Michigan Spine Oncology program. 

Dr. Spratt has published extensively in peer-reviewed journals on the topics of prostate cancer and CNS and spinal malignancies. His laboratory focuses on the interaction of androgen signaling and DNA repair in prostate cancer, and methods to overcome radiation resistance.

Dr. Spratt’s clinical specialties include genitourinary cancers (prostate, bladder, kidney, renal, urinary tract, and penile) and central nervous system tumors of the brain and spine in both children and adults.  Specifically, he has specialized expertise on the use of stereotactic body radiation therapy (SBRT) for the treatment of prostate cancer and for tumors that have metastasized to the spine.